BioCorRxBICX 37 Days Payable is 14,712.31 as of Mar. 2026, which is 12% above its 10-year median of 13,167.25. GuruFocus rates BICX with a GF Score™ of 37/100 and a GF Value™ of $2.76 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 605 Healthcare Providers & Services companies, BioCorRx ranks better than 99.5% on this metric.
BioCorRx's average Accounts Payable for the
three
months ended in Mar. 2026 was $4.19 Mil. BioCorRx's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.03 Mil.
Hence, BioCorRx's Days Payable for the
three
months ended in Mar. 2026 was 14,712.31.
The historical rank and industry rank for BioCorRx's Days Payable or its related term are showing as below:
BICX'
s Days Payable Range Over the Past 10 Years
Min: 837.92 Med: 13167.25 Max: 501601.25
Current: 33128.31
During the past 13 years, BioCorRx's highest Days Payable was 501601.25. The lowest was 837.92. And the median was 13167.25.
BICX's Days Payable is ranked better than 99.5% of 605
companies
in the Healthcare Providers & Services industry
Industry Median: 58
vs BICX: 33128.31
BioCorRx's Days Payable
increased
from Mar. 2025 (0.00) to Mar. 2026 (14,712.31).
It may suggest that BioCorRxdelayed paying its suppliers.
BioCorRx Days Payable Related Terms
BioCorRx Days Payable Historical Data
* Premium members only.
The historical data trend for BioCorRx's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, BioCorRx's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCorRx Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioCorRx's Days Payable distribution charts can be found below:
* The bar in red indicates where BioCorRx's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BioCorRx's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCorRx (BICX) has a Days Payable of 14,712.31 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioCorRx and its competitors. This is 12% above median its historical median of 13,167.25. Over the past decade, BioCorRx's Days Payable has ranged from 837.92 to 501,601.25. According to the industry distribution chart, BioCorRx ranks #3 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 0.5%.
Is BioCorRx's Days Payable too high?
BioCorRx's current Days Payable of 14,712.31 is 12% above median its 10-year median of 13,167.25. Over the past 10 years, this metric has ranged from a low of 837.92 to a high of 501,601.25. The Healthcare Providers & Services industry median Days Payable is 58.00. BioCorRx's value of 14,712.31 is 25266.1% above this industry median. Based on the distribution chart, BioCorRx ranks #3 out of 605 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, BioCorRx has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioCorRx's Days Payable compare to HLYK and AMS?
According to the Healthcare Providers & Services industry distribution chart, BioCorRx ranks #3 out of 605 companies for Days Payable. This places BioCorRx in the top 1% of its industry — outperforming the majority of peers. The industry median Days Payable is 58.00. BioCorRx's value of 14,712.31 is 25266.1% above this benchmark. Historically, BioCorRx's own Days Payable has ranged from 837.92 to 501,601.25 over the past decade. While the company's 10-year median is 13,167.25 vs. the industry median of 58.00, BioCorRx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.00, based on 605 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioCorRx's current Days Payable of 14,712.31 is 25266.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioCorRx and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCorRx's current Days Payable is 14,712.31, which is 12% above median its own 10-year median of 13,167.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCorRx stock overvalued right now?
Based on GuruFocus' analysis, BioCorRx (BICX) is currently considered Possible Value Trap. The stock's GF Value™ is $2.76, compared to a current price of $0.40 — trading 85.5% below its estimated fair value. The current Days Payable is 14,712.31, which is 12% above median its 10-year median of 13,167.25 and 25266.1% above the Healthcare Providers & Services industry median of 58.00. BioCorRx's overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BioCorRx (BICX), the current Days Payable is 14,712.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCorRx (BICX) Overvalued in 2026?
Based on GuruFocus' analysis, BioCorRx stock appears to be undervalued.
The current stock price of $0.40 is trading 85.5% below its estimated GF Value™ of $2.76.
GuruFocus considers BioCorRx to be Possible Value Trap.
Key valuation signals for BICX:
Days Payable: 14,712.31 (12% above median its 10-year median of 13,167.25)
GF Value™: $2.76 vs. price of $0.40 (85.5% below fair value)
Industry Position: 25266.1% above the Healthcare Providers & Services median (#3 of 605)
No single metric tells the full story. See the BICX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCorRx Inc through its subsidiaries, develops and provides addiction treatment solutions, offering an approach to the treatment of substance use and other related disorders. The company makes the Beat Addiction Recovery Program and UnCraveRx Weight Loss Management Program available to healthcare providers to utilize when the healthcare provider determines it is medically appropriate and indicated for their patients. Its products include BICX102 and BICX104. It operates in a single segment.
37GF Score
Get the complete analysis for BICX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BICX has been successfully added to your 
